Ann: MND Trial Successfully Completes First Patient Cohort, page-47

Interesting but always go behind the sensationalist headlines of the mass media because it's not quite as "miraculous" as it seems nor does it necessarily rule out a combined treatment as the targets of Interleukin-2 (IL-2) and mpl are different:

Note the following:

"Overall, the trial results indicated a modest but not statistically significant decrease in the risk of death after 21 months in those people receiving the active drug. However, when the researchers looked at how individuals responded to the treatment, they found that some people responded better than others."

and later:

"The results suggest that IL-2 could be an effective treatment for a sub-group of people with MND, with a certain level of pNHF at diagnosis. While the idea that some treatments may only benefit a sub-group of people with MND is not new (see tofersen for people with SOD1-MND and lithium carbonate for people with a specific variant of the UNC13A gene as examples), it is a novel approach to identify which people may respond to a treatment best based on a measurable biomarker instead of genetic make-up."

Here's the summary of the results:
https://www.myname5doddie.co.uk/whats-on/articles/first-results-emerging-from-mirocals,-a-clinical-trial-of-interleukin-2-in-mnd#:~:text=Data%20from%20a%20phase%202b,having%20in%20people%20with%20MND.


Here's the wikipedia link for the drug they're trialing:
https://en.wikipedia.org/wiki/Interleukin_2


Cheers